Mathematical modelling of [11C]-(+)-PHNO human competition studies

NeuroImage

Volumn 68, Issue , 2013, Pages 119-132

  Searle, Graham E ^a   Beaver, John D ^a   Tziortzi, Andri ^a   Comley, Robert A ^a   Bani, Massimo ^b   Ghibellini, Giulia ^b   Merlo Pich, Emilio ^b   Rabiner, Eugenii A ^a   Laruelle, Marc ^a,c,d   Gunn, Roger N ^a,d,e  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b GSK   (Italy)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

11C (+) PHNO; D2 receptor; D3 receptor; Dopamine; PET

Indexed keywords

CARBON 11; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; GSK 598809; GSK 618334; NAXAGOLIDE; UNCLASSIFIED DRUG; CARBON; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; BINDING AFFINITY; BRAIN REGION; CEREBELLUM; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; IN VITRO STUDY; INTERMETHOD COMPARISON; MALE; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; NEUROIMAGING; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROCESS MODEL; BINDING COMPETITION; BRAIN; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; DRUG ANTAGONISM; METHODOLOGY; MIDDLE AGED; SCINTISCANNING; THEORETICAL MODEL;

ADULT; BINDING, COMPETITIVE; BRAIN; CARBON RADIOISOTOPES; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; MODELS, THEORETICAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

MLCS; MLOWN;

EID: 84871838391     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2012.11.033     Document Type: Article

References (39)

1. Akaike H. A new look at the statistical model identification. IEEE Trans. Autom. Control 1974, 19:716-723.
2. Bouthenet M.L., Souil E., Martres M.P., Sokoloff P., Giros B., Schwartz J.C. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res. 1991, 564:203-219.
3. Delforge J., Bottlaender M., Loc'h C., Guenther I., Fuseau C., Bendriem B., Syrota A., Maziere B. Quantitation of extrastriatal D2 receptors using a very high-affinity ligand (FLB 457) and the multi-injection approach. J. Cereb. Blood Flow Metab. 1999, 19:533-546.
4. Dijkstra D., Rodenhuis N., Vermeulen E.S., Pugsley T.A., Wise L.D., Wikstrom H.V. Further characterization of structural requirements for ligands at the dopamine D(2) and D(3) receptor: exploring the thiophene moiety. J. Med. Chem. 2002, 45:3022-3031.
5. Freedman S.B., Patel S., Marwood R., Emms F., Seabrook G.R., Knowles M.R., McAllister G. Expression and pharmacological characterization of the human D3 dopamine receptor. J. Pharmacol. Exp. Ther. 1994, 268:417-426.
6. Gackenheimer S.L., Schaus J.M., Gehlert D.R. [3H]-quinelorane binds to D2 and D3 dopamine receptors in the rat brain. J. Pharmacol. Exp. Ther. 1995, 274:1558-1565.
7. Gallezot J.D., Beaver J.D., Gunn R.N., Nabulsi N., Weinzimmer D., Singhal T., Slifstein M., Fowles K., Ding Y.S., Huang Y., Laruelle M., Carson R.E., Rabiner E.A. Affinity and selectivity of [(1)(1)C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo. Synapse 2012, 66:489-500.
8. Gehlert D.R., Gackenheimer S.L., Seeman P., Schaus J. Autoradiographic localization of [3H]quinpirole binding to dopamine D2 and D3 receptors in rat brain. Eur. J. Pharmacol. 1992, 211:189-194.
9. Ginovart N., Willeit M., Rusjan P., Graff A., Bloomfield P.M., Houle S., Kapur S., Wilson A.A. Positron emission tomography quantification of [11C]-(+)-PHNO binding in the human brain. J. Cereb. Blood Flow Metab. 2007, 27:857-871.
10. Graff-Guerrero A., Redden L., Abi-Saab W., Katz D.A., Houle S., Barsoum P., Bhathena A., Palaparthy R., Saltarelli M.D., Kapur S. Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. Int. J. Neuropsychopharmacol. 2010, 13:273-287.
11. Gunn R.N., Lammertsma A.A., Hume S.P., Cunningham V.J. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 1997, 6:279-287.
12. Gurevich E.V., Joyce J.N. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology 1999, 20:60-80.
13. Halldin C., Farde L., Hogberg T., Mohell N., Hall H., Suhara T., Karlsson P., Nakashima Y., Swahn C.G. Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J. Nucl. Med. 1995, 36:1275-1281.
14. Heidbreder C.A., Gardner E.L., Xi Z.X., Thanos P.K., Mugnaini M., Hagan J.J., Ashby C.R. The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Res. Brain Res. Rev. 2005, 49:77-105.
15. Joyce J.N., Millan M.J. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov. Today 2005, 10:917-925.
16. Lammertsma A.A., Hume S.P. Simplified reference tissue model for PET receptor studies. Neuroimage 1996, 4:153-158.
17. Levant B. Differential distribution of D3 dopamine receptors in the brains of several mammalian species. Brain Res. 1998, 800:269-274.
18. Levant B., Grigoriadis D.E., DeSouza E.B. [3H]quinpirole binding to putative D2 and D3 dopamine receptors in rat brain and pituitary gland: a quantitative autoradiographic study. J. Pharmacol. Exp. Ther. 1993, 264:991-1001.
19. Levant B., Grigoriadis D.E., De Souza E.B. Relative affinities of dopaminergic drugs at dopamine D2 and D3 receptors. Eur. J. Pharmacol. 1995, 278:243-247.
20. Malmberg A., Mohell N. Characterization of [3H]quinpirole binding to human dopamine D2A and D3 receptors: effects of ions and guanine nucleotides. J. Pharmacol. Exp. Ther. 1995, 274:790-797.
21. Marner L., Gillings N., Comley R.A., Baare W.F., Rabiner E.A., Wilson A.A., Houle S., Hasselbalch S.G., Svarer C., Gunn R.N., Laruelle M., Knudsen G.M. Kinetic modeling of 11C-SB207145 binding to 5-HT4 receptors in the human brain in vivo. J. Nucl. Med. 2009, 50:900-908.
22. Millan M.J., Brocco M. Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138. Therapie 2008, 63:187-229.
23. Mizrahi R., Houle S., Vitcu I., Ng A., Wilson A.A. Side effects profile in humans of (11)C-(+)-PHNO, a dopamine D(2/3) agonist ligand for PET. J. Nucl. Med. 2010, 51:496-497.
24. Mukherjee J., Yang Z.Y., Brown T., Lew R., Wernick M., Ouyang X., Yasillo N., Chen C.T., Mintzer R., Cooper M. Preliminary assessment of extrastriatal dopamine D-2 receptor binding in the rodent and nonhuman primate brains using the high affinity radioligand, 18F-fallypride. Nucl. Med. Biol. 1999, 26:519-527.
25. Murray A.M., Ryoo H.L., Gurevich E., Joyce J.N. Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:11271-11275.
26. Narendran R., Frankle W.G., Mason N.S., Laymon C.M., Lopresti B.J., Price J.C., Kendro S., Vora S., Litschge M., Mountz J.M., Mathis C.A. Positron emission tomography imaging of D(2/3) agonist binding in healthy human subjects with the radiotracer [(11)C]-N-propyl-norapomorphine: preliminary evaluation and reproducibility studies. Synapse 2009, 63:574-584.
27. Narendran R., Mason N.S., Chen C.M., Himes M., Keating P., May M.A., Rabiner E.A., Laruelle M., Mathis C.A., Frankle W.G. Evaluation of dopamine D/ specific binding in the cerebellum for the positron emission tomography radiotracer [(1)(1)C]FLB 457: implications for measuring cortical dopamine release. Synapse 2011, 65:991-997.
28. Parsey R.V., Slifstein M., Hwang D.R., Abi-Dargham A., Simpson N., Mawlawi O., Guo N.N., Van Heertum R., Mann J.J., Laruelle M. Validation and reproducibility of measurement of 5-HT1A receptor parameters with [carbonyl-11C]WAY-100635 in humans: comparison of arterial and reference tisssue input functions. J. Cereb. Blood Flow Metab. 2000, 20:1111-1133.
29. Rabiner E.A., Slifstein M., Nobrega J., Plisson C., Huiban M., Raymond R., Diwan M., Wilson A.A., McCormick P., Gentile G., Gunn R.N., Laruelle M.A. In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: studies in non-human primates and transgenic mice. Synapse 2009, 63:782-793.
30. Schwarz G. Estimating the dimension of a model. Ann. Stat. 1978, 6:461-464.
31. Searle G., Beaver J.D., Comley R.A., Bani M., Tziortzi A., Slifstein M., Mugnaini M., Griffante C., Wilson A.A., Merlo-Pich E., Houle S., Gunn R., Rabiner E.A., Laruelle M. Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Biol. Psychiatry 2010, 68:392-399.
32. Seeman P., Wilson A., Gmeiner P., Kapur S. Dopamine D2 and D3 receptors in human putamen, caudate nucleus, and globus pallidus. Synapse 2006, 60:205-211.
33. Shotbolt P., Tziortzi A.C., Searle G.E., Colasanti A., van der Aart J., Abanades S., Plisson C., Miller S.R., Huiban M., Beaver J.D., Gunn R.N., Laruelle M., Rabiner E.A. Within-subject comparison of [(11)C]-(+)-PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans. J. Cereb. Blood Flow Metab. 2012, 32(1):127-136. (Jan). 10.1038/jcbfm.2011.115.
34. Sibley D.R., De Lean A., Creese I. Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. J. Biol. Chem. 1982, 257:6351-6361.
35. Sokoloff P., Diaz J., Le Foll B., Guillin O., Leriche L., Bezard E., Gross C. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol. Disord. Drug Targets 2006, 5:25-43.
36. Tziortzi A.C., Searle G.E., Tzimopoulou S., Salinas C., Beaver J.D., Jenkinson M., Laruelle M., Rabiner E.A., Gunn R.N. Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy. Neuroimage 2011, 54:264-277.
37. van Vliet L.A., Rodenhuis N., Dijkstra D., Wikstrom H., Pugsley T.A., Serpa K.A., Meltzer L.T., Heffner T.G., Wise L.D., Lajiness M.E., Huff R.M., Svensson K., Sundell S., Lundmark M. Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b-tetrahydro-4-n-propyl-2H,5H [1]b enzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907). J. Med. Chem. 2000, 43:2871-2882.
38. Willeit M., Ginovart N., Kapur S., Houle S., Hussey D., Seeman P., Wilson A.A. High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(+)-PHNO. Biol. Psychiatry 2006, 59:389-394.
39. Wilson A.A., McCormick P., Kapur S., Willeit M., Garcia A., Hussey D., Houle S., Seeman P., Ginovart N. Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J. Med. Chem. 2005, 48:4153-4160.